Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Transactions

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the acquisition and disposal of company stock on April 1st and 2nd, 2024.

Summary

• Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals, reported changes in beneficial ownership of company stock.
• On April 1, 2024, 225 shares of common stock were disposed of at a price of $418.10.
• On April 2, 2024, 240 shares of common stock were sold at a price of $419.
• Following these transactions, Ms. Ambrose beneficially owns 7,500 shares of Vertex Pharmaceuticals common stock.
• The sale on April 2, 2024, was executed under a pre-arranged trading plan (Rule 10b5-1) established on February 28, 2023.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and helps ensure fair market practices.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions are relatively small in scale, suggesting routine portfolio management rather than a significant shift in sentiment.
• Similar filings are regularly made by executives at comparable pharmaceutical companies like Amgen (AMGN) and Gilead Sciences (GILD).

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders, as they represent a small portion of the company's outstanding shares.

Key Dates